<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890912</url>
  </required_header>
  <id_info>
    <org_study_id>SPARTACUS II</org_study_id>
    <nct_id>NCT04890912</nct_id>
  </id_info>
  <brief_title>Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II</brief_title>
  <acronym>SPARTACUSII</acronym>
  <official_title>Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II: A Phase II Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Victoria Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Credit Valley Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Regional Cancer Program, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjuvant radiotherapy (RT) plays an important role in reducing the risks of local recurrence&#xD;
      after surgery in uterine cancers. Standard adjuvant pelvic radiation treatment targets the&#xD;
      pelvic lymph nodes, the post-operative bed, and the upper vagina and is typically treated&#xD;
      with intensity modulated radiation therapy (IMRT) which has been shown to improve patient&#xD;
      reported gastrointestinal (GI) and genitourinary (GU) toxicities. Although pelvic radiation&#xD;
      has been shown to be effective at decreasing locoregional recurrences, patient quality of&#xD;
      life and experience can be significantly impacted as pelvic RT comprises of daily radiation&#xD;
      for 25 daily treatments, which can be a substantial burden on patients with this disease.&#xD;
      Hypofractionated radiotherapy to a dose of 30 Gy in 5 fractions (6 Gy given every other day)&#xD;
      for adjuvant radiation treatment in uterine cancer is hypothesized to result in similar rates&#xD;
      of acute gastrointestinal toxicities as conventional fractionated radiation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute bowel toxicity</measure>
    <time_frame>Baseline to 2 years following RT completion</time_frame>
    <description>To compare the acute bowel toxicities associated with hypofractionated vs conventional adjuvant pelvic radiation as measured by the The Expanded Prostate Cancer Index Composite (EPIC) questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute bowel toxicities</measure>
    <time_frame>Baseline to 2 years following RT completion</time_frame>
    <description>To compare the acute bowel toxicities associated with hypofractionated treatment and conventional fractionation in adjuvant pelvic radiation for endometrial cancers using the Common Terminology Criteria for Adverse Events (CTCAE v5.0) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute urinary toxicities through CTCAE</measure>
    <time_frame>Baseline to 2 years following RT completion</time_frame>
    <description>To compare the acute urinary toxicities associated with hypofractionated treatment and conventional fractionation in adjuvant pelvic radiation for endometrial cancers using the Common Terminology Criteria for Adverse Events (CTCAE v5.0) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute urinary toxicities through EPIC</measure>
    <time_frame>Baseline to 2 years following RT completion</time_frame>
    <description>To compare the acute urinary toxicities associated with hypofractionated treatment and conventional fractionation in adjuvant pelvic radiation for uterine cancer as measured by EPIC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local- regional failure</measure>
    <time_frame>Baseline to 2 years following RT completion</time_frame>
    <description>To compare presence of tumour through physical exam or radiologic imaging between hypofractionated treatment and conventional fractionation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Baseline to 2 years following RT completion</time_frame>
    <description>To compare disease-free survival of hypofractionated treatment and conventional fractionation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using EORTC QLQ-30 and endometrial module (EN-24)</measure>
    <time_frame>Baseline to 2 years following RT completion</time_frame>
    <description>To compare the effect of hypofractionated treatment and conventional fractionation on quality of life using the using EORTC (European Organisation for Research and Treatment of Cancer) core questionnaire (QLQ-C30) with EN-24 companion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of GU toxicity, EORTC, and EPIC</measure>
    <time_frame>Baseline to 2 years following RT completion</time_frame>
    <description>To measure correlations between GU toxicity and EORTC questionnaire versus GU toxicity and EPIC questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Conventional Fractionation Pelvic Radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the conventional fractionation arm will be treated with intensity-modulated or volumetric arc therapy technique as per standard protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Hypofractionated Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to hypofractionation will be treated the stereotactic hypofractionated technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional Fractionation</intervention_name>
    <description>Dose prescribed is 45 Gy in 25 fractions (1.8 Gy per fraction) delivered daily over 5 weeks.</description>
    <arm_group_label>Conventional Fractionation Pelvic Radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionation</intervention_name>
    <description>Dose prescribed is 30 Gy in 5 fractions (6 Gy per fraction) delivered every other day over 11 days. There will be a minimum of 36 hours and maximum of 96 hours between fractions. The entire course of treatment should be completed within no less than 10 days.</description>
    <arm_group_label>Stereotactic Hypofractionated Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with histologically confirmed endometrial adenocarcinoma, serous or clear cell&#xD;
             carcinoma.&#xD;
&#xD;
          2. Patient is a candidate for adjuvant pelvic radiation for uterine cancer (+/- vault&#xD;
             brachytherapy), meeting one of the following conditions:&#xD;
&#xD;
             High grade histology (including serous and clear cell) OR Outer-half myometrial&#xD;
             invasion and International Federation of Gynecology and Obstetrics (FIGO) grade 1-2 OR&#xD;
             FIGO stage II - III.&#xD;
&#xD;
          3. Patients who are to receive adjuvant systemic therapy sequentially in addition to&#xD;
             pelvic radiotherapy will be eligible.&#xD;
&#xD;
          4. Age â‰¥18 years.&#xD;
&#xD;
          5. Patient is willing and able to give informed consent to participate in this clinical&#xD;
             trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has had prior pelvic radiotherapy.&#xD;
&#xD;
          2. Patient has a contraindication to pelvic radiotherapy, such as but not limited to a&#xD;
             connective tissue disease or inflammatory bowel disease.&#xD;
&#xD;
          3. Patient planned for concurrent chemoradiation therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Leung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathy Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Gladwish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Victoria Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anika Mohan</last_name>
    <phone>416-480-5000</phone>
    <phone_ext>89828</phone_ext>
    <email>anika.mohan@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nithla Mohanathas</last_name>
    <phone>416-480-5000</phone>
    <phone_ext>85838</phone_ext>
    <email>nithla.mohanathas@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Gladwish, MD</last_name>
      <email>gladwisha@rvh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Adam Gladwish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Skliarenko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David D'Souza, MD</last_name>
      <email>david.dsouza@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>David D'Souza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucas Mendez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vikram Velker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jasper Yuen, MD</last_name>
      <email>jyuen@cvh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Jasper Yuen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anika Mohan</last_name>
      <email>anika.mohan@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Eric Leung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Barnes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amandeep Taggar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melanie Davidson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Loblaw, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elysia Donovan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Cheung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Han, MD</last_name>
      <email>kathy.han@rmp.uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Kathy Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Eric Leung</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>endometrial cancer</keyword>
  <keyword>uterine cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

